Cargando…

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment

(1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV infection. (2) Methods: In this retrospective hospital-based cohort study, we screened all lung cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Po-Hsin, Huang, Yen-Hsiang, Hsu, Yu-Wei, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Lin, Ho, Lee, Teng-Yu, Tseng, Jeng-Sen, Chang, Gee-Chen, Yang, Tsung-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820864/ https://www.ncbi.nlm.nih.gov/pubmed/36615034 http://dx.doi.org/10.3390/jcm12010231

Ejemplares similares

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
por: Lee, Po-Hsin, et al.
Publicado: (2021)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
por: Wu, Jia-Jun, et al.
Publicado: (2022)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2022)

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
por: Ou, Wei-Fan, et al.
Publicado: (2023)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018
por: Tseng, Jeng-Sen, et al.
Publicado: (2022)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)

Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients
por: Lin, Chun, et al.
Publicado: (2021)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid
por: Liao, Pei-Ya, et al.
Publicado: (2022)

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
por: Chen, Hsuan-Yu, et al.
Publicado: (2016)

Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
por: Su, Sheng-Fang, et al.
Publicado: (2021)

CXCR4 Antagonist Reduced the Incidence of Acute Rejection and Controlled Cardiac Allograft Vasculopathy in a Swine Heart Transplant Model Receiving a Mycophenolate-based Immunosuppressive Regimen
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Prognostic Factors to Predict ICU Mortality in Patients with Severe ARDS Who Received Early and Prolonged Prone Positioning Therapy
por: Lee, Po-Hsin, et al.
Publicado: (2021)

Gallic Acid Induces a Reactive Oxygen Species-Provoked c-Jun NH(2)-Terminal Kinase-Dependent Apoptosis in Lung Fibroblasts
por: Chen, Chiu-Yuan, et al.
Publicado: (2013)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
por: Huang, Yu-Tsung, et al.
Publicado: (2018)

Are the sensorimotor control capabilities of the hands the factors influencing hand function in people with schizophrenia?
por: Lai, Yu-Jen, et al.
Publicado: (2023)

Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma
por: Raghav, Lovely, et al.
Publicado: (2020)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
por: Chen, Yen-Liang, et al.
Publicado: (2023)

EGFR Tyrosine Kinase Inhibitor–Associated Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
por: Chang, Hsu-Liang, et al.
Publicado: (2020)

High-Sensitivity C-Reactive Protein Predicts Mortality and Technique Failure in Peritoneal Dialysis Patients
por: Liu, Shou-Hsuan, et al.
Publicado: (2014)

Mechanism of Antigen Presentation and Specificity of Antibody Cross-Reactivity Elicited by an Oligosaccharide-Conjugate Cancer Vaccine
por: Wang, Szu-Wen, et al.
Publicado: (2023)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses
por: Wang, Hsian-Yu, et al.
Publicado: (2016)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Chrysophanol Regulates Cell Death, Metastasis, and Reactive Oxygen Species Production in Oral Cancer Cell Lines
por: Hsu, Po-Chih, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7gjnpasvnmidrl65cr7qia2kul